Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

2.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.

3.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. No abstract available.

4.

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.

Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, Hong H, Padeganeh A, Bedell V, Cao T, Khaled SK, Malki MMA, Salhotra A, Ali H, Aribi A, Palmer J, Aoun P, Spielberger R, Stein AS, Snyder D, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger D, Forman SJ, Pullarkat V, Marcucci G, Pillai R, Nakamura R.

Haematologica. 2017 Dec;102(12):2030-2038. doi: 10.3324/haematol.2017.172544. Epub 2017 Sep 29.

5.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J.

Biol Blood Marrow Transplant. 2017 Apr;23(4):618-624. doi: 10.1016/j.bbmt.2017.01.067. Epub 2017 Jan 10.

6.

Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.

Aldoss I, Stiller T, Song J, Al Malki M, Ali H, Salhotra A, Aribi A, Khaled S, Gaytan P, Murata-Collins J, Palmer J, Snyder D, O'Donnell M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2017 Feb;92(2):E18-E19. doi: 10.1002/ajh.24604. No abstract available.

7.

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.

Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW, Koeffler HP.

Mol Carcinog. 2014 Sep;53(9):722-35. doi: 10.1002/mc.22024. Epub 2013 Mar 8.

8.

The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.

Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP.

Int J Cancer. 2013 Jun 15;132(12):2730-7. doi: 10.1002/ijc.27950. Epub 2012 Dec 13.

9.

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H.

J Clin Oncol. 2009 Nov 10;27(32):5425-30. doi: 10.1200/JCO.2009.22.6688. Epub 2009 Oct 5.

10.

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Cancer. 2008 Sep 15;113(6):1338-43. doi: 10.1002/cncr.23718.

11.

Biphenotypic acute leukaemia: a case series.

Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F.

Br J Haematol. 2007 Jul;138(2):213-6.

PMID:
17593028
12.

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.

Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE.

Cancer. 2007 Apr 1;109(7):1355-9.

13.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H.

Cancer. 2007 Feb 15;109(4):713-7.

14.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.

Cancer. 2007 Jan 15;109(2):265-73.

15.

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F.

Leuk Res. 2007 Jul;31(7):939-45. Epub 2006 Oct 12.

PMID:
17045649
16.

Novel approaches in the treatment of systemic mastocytosis.

Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S.

Cancer. 2006 Oct 1;107(7):1429-39. Review.

17.

Novel agents in acute myeloid leukemia.

Aribi A, Ravandi F, Giles F.

Cancer J. 2006 Mar-Apr;12(2):77-91. Review.

PMID:
16630396
18.

Loss of RAB25 expression in breast cancer.

Cheng JM, Ding M, Aribi A, Shah P, Rao K.

Int J Cancer. 2006 Jun 15;118(12):2957-64.

19.

Effects of glial toxins on extracellular acidification in the hippocampal CA1 region in vivo.

Stringer JL, Aribi AM.

Epilepsy Res. 2003 May;54(2-3):163-70.

PMID:
12837567
20.

Modulation of the in vivo effects of gabapentin by vigabatrin and SKF89976A.

Stringer JL, Aribi AM.

Epilepsy Res. 2002 Dec;52(2):129-37.

PMID:
12458029
21.
22.

[Bladder hernia apropos of a case report].

Njeh M, Mnif J, Aribi A, Bahloul A, Mhiri MN.

Acta Urol Belg. 1996 Sep;64(3):55-7. French.

PMID:
8984856

Supplemental Content

Support Center